Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details - PubMed
Clostridioides difficile infection (CDI) remains a significant contributor to healthcare costs and morbidity due to high rates of recurrence. Currently, available antibiotic treatment strategies further disrupt the fecal microbiome and do not address the alterations in commensal flora (dysbio …